A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Two of 6 patients (33.3%) with SCCOHT achieved durable CR/iCR and long-term survival with ipilimumab plus nivolumab. Correlative studies to determine response and resistance markers are ongoing.
Authors
- Tanya Pejovic
- Liam Il‐Young Chung (ORCID: https://orcid.org/0000-0001-6541-793X)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-0044-9719)
- Hye Sung Kim (ORCID: https://orcid.org/0000-0002-2182-301X)
- Megan Othus (ORCID: https://orcid.org/0000-0001-8176-6371)
- Charles D. Blanke
- Helen X Chen
- Khine Z. Win
- Christopher W. Ryan (ORCID: https://orcid.org/0000-0002-4259-1123)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Sajeve Thomas (ORCID: https://orcid.org/0000-0002-0925-3325)
- Sandip Pravin Patel (ORCID: https://orcid.org/0000-0002-8387-4840)
- Young Kwang Chae (ORCID: https://orcid.org/0000-0003-1557-7235)
- Christine M. McLeod
- HOWARD Z. STREICHER (ORCID: https://orcid.org/0000-0003-3683-9804)
- William R. Robinson
- Raid Aljumaily
Institutions
- Northwestern University (US)
- Tulane University (US)
- Orlando Health (US)
- Oregon Health & Science University (US)
- Medical College of Wisconsin (US)
- University of Florida Health (US)
- Rideout Memorial Hospital (US)
- University of California San Diego (US)
- Florida Hospital Cancer Institute (US)
- Comprehensive Cancer Center Vienna (AT)
- Temple University Hospital (US)
- University of California San Diego Medical Center (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- New Mexico Cancer Center (US)
- Data Management Services (United States) (US)
- Cancer Institute of Florida (US)
- SWOG Cancer Research Network (US)
- Moores Cancer Center
- OU Health
- UC Davis Comprehensive Cancer Center
- OHSU Knight Cancer Institute
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Cancer Communications
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1002/cac2.70020
- Citations
- 1
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Bristol-Myers Squibb
- National Institutes of Health
- National Cancer Institute